Souhaitez-vous accéder aux communiqués récents ?

Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data...

New York City, NY, March 18, 2026 (GLOBE NEWSWIRE) -- Memo Genesis is now launching in global markets, with initial availability across the United States and Canada. As interest in cognitive...

COMPLETION OF SOCIETE GENERALE’S EUR 1,462 MILLION SHARE BUY-BACK PROGRAMME FOR CANCELLATION PURPOSE Regulated Information Paris, 18 March 2026 Societe Generale announces the completion of its...

Azalea highlights Nature publication demonstrating in vivo CAR T engineering through site-specific genomic integration with durable anti-tumor activity.

Oral presentation of Ph 1a clinical data highlights potential best-in-class drug profile in heavily pretreated patients with PI3Ka-mutant metastatic breast cancer and other solid tumors Overall,...

MALVERN, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Vishay Intertechnology, Inc. (NYSE: VSH) today introduced a new space-grade, surface-mount common mode choke designed to provide EMI filtering and...

Fatboy Canada launches its Spring/Summer collection: modular lounges, dining sets, lighting, and bean bags to create the ultimate outdoor living space.

WALTHAM, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Paragonix Technologies, a pioneer in organ transplant technologies and services, today announced the completion of the 1,000th clinical case using...

TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice...

ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates...